New drug cocktail aims to shrink Hard-to-Treat cancers
NCT ID NCT07111546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75, in good physical condition, and have a life expectancy of at least 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LBL-024 (an experimental drug) combined with cisplatin, gemcitabine, and bevacizumab
- What this could lead to
- If successful, this combination could shrink tumors in people with advanced solid cancers, offering a new treatment option.
- What could go wrong
- This is an early Phase 2 trial with only 140 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOUR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, Jiangxi, 330029, China
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
-
Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310016, China
-
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITINGNanning, Guangxi, 530021, China
-
Xiangyang Central Hospital
RECRUITINGXiangyang, Hubei, 441106, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
-
Zhongshan Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can a smart drug home in on Hard-to-Treat cancers?